What made Incyte rise last week?
This article was originally published in Scrip
Executive Summary
The discontinuation of Sanofi's JAK2 inhibitor for myelofibrosis, fedratinib (SAR302503), despite previous positive results from Phase III trials was a shock to many on 18 November. As might be expected, the elimination of impending competition was seen as a boon for the maker of the only approved JAK inhibitor for myelofibrosis, Incyte (which together with Novartis sells Jakafi/Jakavi (ruxolitinib).